<DOC>
	<DOCNO>NCT00003216</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . It yet know treatment regimen effective pancreatic cancer . PURPOSE : Randomized phase III trial compare effectiveness fluorouracil gemcitabine plus radiation therapy treat patient cancer pancreas undergone surgery .</brief_summary>
	<brief_title>Fluorouracil , Gemcitabine , Radiation Therapy Treating Patients With Cancer Pancreas</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall disease-free survival patient resect adenocarcinoma pancreas treat adjuvant fluorouracil-based chemoradiotherapy precede follow fluorouracil vs gemcitabine . - Compare local-regional distant disease control patient treat regimen . - Compare acute late toxic effect regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord nodal involvement ( yes v ) , tumor diameter ( le 3 cm v 3 cm great ) , surgical margin ( negative v positive v unknown ) . Patients randomize one two treatment arm . - Arm I : Beginning 3-8 week definitive surgical resection , patient receive fluorouracil IV continuously 3 week . Beginning 1-2 week later , patient receive fluorouracil IV continuously concurrently radiotherapy 5 day week 5.5 week . Beginning 3-5 week completion chemoradiotherapy , patient receive fluorouracil IV continuously 4 week every 6 week 2 course . - Arm II : Beginning 3-8 week definitive surgical resection , patient receive gemcitabine IV weekly 3 week . Beginning 1-2 week later , patient receive chemoradiotherapy arm I . Beginning 3-5 week completion chemoradiotherapy , patient receive gemcitabine IV weekly 3 week every 4 week 3 course . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 518 patient accrue study within 8.6 year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma pancreas Stage T14 , N01 ( stage IIVA ) No M1 NX stag Primary tumor pancreas ( pancreatic head , neck , uncinate process , body/tail ) maximum diameter/dimension tumor status surgical margin know Prior potentially curative gross resection within 38 week study No nonadenocarcinomas , adenosquamous carcinoma , islet cell carcinoma , cystadenomas , cystadenocarcinomas , carcinoid tumor , duodenal carcinoma , distal bile duct carcinoma , ampullary carcinoma No recurrent disease Postresection CA199 level require PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 5 time ULN Renal : Creatinine great 1.5 time ULN Other : No significant nausea vomit No prior malignancy within past 5 year except nonmelanomatous skin cancer carcinoma situ cervix Able maintain adequate nutrition ( least 1,500 calories/day ) Feeding tube allow Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>